Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc. insiders are currently net sellers of VIRX stock, showing bearish sentiment over the past 90 days. Total sales of $403.0K outpace purchases of $93.5K, creating a net outflow of $309.5K.

Viracta Therapeutics, Inc. has 14 active insiders who have filed SEC Form 4 transactions in the past 90 days. Ivor Royston (Executive) leads with 21 transactions totaling $170.1K. Lisa Rojkjaer (Executive) follows with 15 transactions worth $99.3K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Viracta Therapeutics, Inc.'s current score of 19/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Nov 25, 2024, when Pomerantz Roger (Executive) disposed of 9,034 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, VIRX insider trading sentiment is currently bearish with an Alignment Score of 19/100. The negative net flow of $309.5K shows more selling than buying. However, 0% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Viracta Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At VIRX, we track all Form 4 filings—currently showing 94 transactions from 14 insiders over 90 days.

A 10b5-1 plan allows Viracta Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At VIRX, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at VIRX appears discretionary, making insider signals more meaningful.

You can monitor Viracta Therapeutics, Inc. (VIRX) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 14 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Viracta Therapeutics, Inc.'s current score of 19/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $93.5K in purchases versus $403.0K in sales over 90 days, resulting in a net flow of -$309.5K.

SEC Form 4 filings are mandatory reports that Viracta Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At VIRX, the most common type is "M" with 28 occurrences. The most recent Form 4 was filed on Nov 25, 2024 by Pomerantz Roger.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Viracta Therapeutics, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at VIRX represents discretionary decisions with more informational value.